Guideli nes for Pathologic Diagnosis of Mesothelioma 2023 Update of the Consensus Statement From the International Mesothelioma Interest Group

被引：15

作者：

Husain, Aliya N. ^{[1
]}

Chapel, David B. ^{[2
]}

Attanoos, Richard ^{[3
,4
,5
]}

Beasley, Mary Beth ^{[6
]}

Brcic, Luka ^{[7
]}

Butnor, Kelly ^{[8
]}

Chirieac, Lucian R. ^{[9
]}

Churg, Andrew ^{[10
]}

Dacic, Sanja ^{[11
]}

Galateau-Salle, Francoise ^{[12
]}

Hiroshima, Kenzo ^{[13
]}

Hung, Yin P. ^{[14
]}

Klebe, Sonja ^{[15
]}

Krausz, Thomas ^{[1
]}

Khoor, Andras ^{[16
]}

Litzky, Leslie ^{[17
]}

Marchevsky, Alberto ^{[18
]}

Nabeshima, Kazuki ^{[19
]}

Nicholson, Andrew G. ^{[20
]}

Pavlisko, Elizabeth N. ^{[21
]}

Roden, Anja C. ^{[22
]}

Roggli, Victor ^{[21
]}

Sauter, Jennifer L. ^{[23
]}

Schulte, Jefree J. ^{[24
]}

Sheaff, Michael ^{[25
]}

Travis, William D. ^{[23
]}

Tsao, Ming-Sound ^{[26
,27
]}

Walts, Ann E. ^{[18
]}

Colby, Thomas V. ^{[28
]}

机构：

[1] Univ Chicago, Dept Pathol, Chicago, IL USA

[2] Univ Michigan, Dept Pathol, Ann Arbor, MI USA

[3] Univ Hosp Wales, Dept Cellular Pathol, Cardiff, Wales

[4] Univ Hosp Wales, Sch Med, Cardiff, Wales

[5] Cardiff Univ, Cardiff, Wales

[6] Mt Sinai Hosp, Dept Pathol, New York, NY USA

[7] Med Univ Graz, Diagnost & Res Inst Pathol, Graz, Austria

[8] Univ Vermont, Coll Med, Dept Pathol & Lab Med, Burlington, VT USA

[9] Brigham & Womens Hosp, Dept Pathol, Boston, MA USA

[10] Univ British Columbia, Dept Pathol, Vancouver, BC, Canada

[11] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA

[12] Lab Anat Pathol & Neuropathol, Caen, France

[13] Chiba Univ, Grad Sch Med, Dept Biochem & Genet, Chiba, Japan

[14] Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA

[15] SA Pathol & Flinders Univ, Dept Anat Pathol, Bedford Pk, Australia

[16] Mayo Clin, Dept Lab Med & Pathol, Jacksonville, FL USA

[17] Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA USA

[18] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA USA

[19] Fukuoka Tokushukai Hosp, Dept Clin Pathol, Kasuga City, Fukuoka, Japan

[20] Royal Brompton & Harefield NHS Fdn Trust, Dept Histopathol, London, England

[21] Duke Univ, Med Ctr, Dept Pathol, Durham, NC USA

[22] Mayo Clin, Dept Pathol & Lab Med, Rochester, MN USA

[23] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, New York, NY USA

[24] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA

[25] Barts Hlth NHS Trust, Dept Cellular Pathol, London, England

[26] Univ Hlth Network, Dept Lab Med & Pathobiol, Toronto, ON, Canada

[27] Univ Toronto, Toronto, ON, Canada

[28] Mayo Clin Arizona, Lab Med & Pathol, Scottsdale, AZ USA

来源：

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE | 2024年 / 148卷 / 11期

关键词：

MALIGNANT PLEURAL MESOTHELIOMA; DIFFERENTIATED PAPILLARY MESOTHELIOMA; IN-SITU HYBRIDIZATION; RENAL-CELL CARCINOMA; BAP1; IMMUNOHISTOCHEMISTRY; SARCOMATOID MESOTHELIOMA; EPITHELIOID MESOTHELIOMA; PERITONEAL MESOTHELIOMA; P16; FISH; ALK REARRANGEMENTS;

D O I：

10.5858/arpa.2023-0304-RA

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

center dot Context. - Mesothelioma is an uncommon tumor that can be difficult to diagnose. Objective.-To provide updated, practical guidelines for the pathologic diagnosis of mesothelioma. Data Sources.-Pathologists involved in the International Mesothelioma Interest Group and others with expertise in mesothelioma contributed to this update. Reference material includes peer-reviewed publications and textbooks. Conclusions.-There was consensus opinion regarding guidelines for (1) histomorphologic diagnosis of mesothelial tumors, including distinction of epithelioid, biphasic, and sarcomatoid mesothelioma; recognition of morphologic variants and patterns; and recognition of common morphologic pitfalls; (2) molecular pathogenesis of mesothelioma; (3) application of immunohistochemical markers to establish mesothelial lineage and distinguish mesothelioma from common morphologic differentials; (4) application of ancillary studies to distinguish benign from malignant mesothelial proliferations, including BAP1 and MTAP immunostains; novel immunomarkers such as Merlin and p53; fluorescence in situ hybridization (FISH) for homozygous deletion of CDKN2A; and novel molecular assays; (5) practical recommendations for routine reporting of mesothelioma, including grading epithelioid mesothelioma and other prognostic parameters; (6) diagnosis of mesothelioma in situ; (7) cytologic diagnosis of mesothelioma, including use of immunostains and molecular assays; and (8) features of nonmalignant peritoneal mesothelial lesions. (Arch Pathol Lab Med. 2024;148:1251-1271; doi: 10.5858/ arpa.2023-0304-RA)

引用

页码：1251 / 1271

页数：21

共 180 条

[1] Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma [J].